Sue Friedman on Informed Decision-Making in Hereditary Cancers

Article

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the importance of informed decision-making.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the importance of informed decision-making.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
4 experts in this video
Related Content
graphic of a person with breast tumors

JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

Chris Ryan
July 28th 2025
Article

Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Graphic of a breast with a tumor

Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

Jax DiEugenio
July 14th 2025
Article

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

graphic of a breast with a tumor

KN026/KN046 Combo Yields Durable Responses in HER2+ mBC

Jax DiEugenio
July 7th 2025
Article

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Graphic of a breast with tumors

Gedatolisib Combos Show Early Activity in mCRPC, Metastatic Breast Cancer

Tim Cortese
July 3rd 2025
Article

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.